KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Financing Cash Flow · Q4 FY2026 · quarter ended Dec 2025

Financing cash flow of $1.47M in Q4 FY2026

Q4 FY2026 financing cash flow was $1.47M. Trailing-twelve-month financing cash flow was $22.93M.

Context

  • Financing cash flow amounted to 220.9% of revenue in FY2026.
  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near $1.47M or moves back toward the trailing-twelve-month quarterly average of $5.73M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.47M— QoQ
Last fiscal yearDec 2025
$162.64M— YoY
LTMDec 2025
$22.93M— YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2026
162.64M USD
Year-over-year change
+1.8%
4-year CAGR
+218.5%

Financing Cash Flow vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 financing cash flow of $22.93M is the 6th largest of the 10 companies compared; the peer median is $6.43M.
  • Financing cash flow amounts to 19.8% of revenue for KALV, versus a peer median of 76.6%.
KALV Competitors Peer median
Financing Cash Flow for KALV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$256.78M -1.3%+662.8%—
VSTMVerastem, Inc.LTM Mar 2026$224.57M +85.0%+72.0%452.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$151.21M +55.9%—191.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$124.44M +575.7%+232.1%141.0%
OMEROmeros CorporationLTM Mar 2026$62.31M +66.7%—629.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$22.93M ——19.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$10.8M +25.0%-54.9%3.6%
PRTAProthena Corporation plcLTM Mar 2026$7.03M -1150.0%—12.1%
GOSSGossamer Bio, Inc.LTM Mar 2026$6.43M +176.3%-62.0%11.6%
BCYCBicycle Therapeutics plcLTM Mar 2026$143.84K -100.0%—0.2%
Peer median (excluding KALV) $6.43M+55.9%+72.0%76.6%

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Depreciation & Amortization743K718K816K941K1.45M
Deferred Income Tax00000
Stock-Based Compensation09.92M21.92M12.29M0
Change in Working Capital(12.32M)7.41M15.17M15.04M954K
Accounts Receivables(5.2M)(2.32M)8.18M(3.62M)(7.4M)
Inventory0000(3.43M)
Accounts Payables1.69M1.11M4.32M(4.97M)4.19M
Other Working Capital(8.81M)8.62M2.67M23.63M7.59M
Other Non-Cash Items15.78M(407K)(485K)2.27M80.26M
Operating Cash Flow(78.13M)(75.26M)(89.23M)(152.91M)(81.62M)
Capital Expenditures(931K)(1.2M)(443K)(434K)(1.71M)
Acquisitions (Net)00000
Purchases of Investments(136.92M)(98.25M)(189.23M)(30.57M)(84.78M)
Sales of Investments195.71M140.86M104.96M122.52M105.36M
Other Investing Activities00(401K)00
Investing Cash Flow57.86M41.42M(84.72M)91.02M18.68M
Debt Repayment00098.04M160.72M
Common Stock Issued1.58M56.58M96.95M61.69M1.92M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.53M53.77M00
Financing Cash Flow1.58M58.12M150.71M159.73M162.64M
Effect of Forex Changes(1.17M)1.24M(1.21M)1.98M(1.98M)
Net Change in Cash(19.86M)25.51M(24.45M)99.83M97.73M
Free Cash Flow(79.07M)(76.46M)(89.67M)(153.34M)(83.33M)

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.